• Pacira Biosciences reported publication of two-year Phase 1 results for PCRX-201, its investigational gene therapy for knee osteoarthritis.
• Results were already presented via the journal publication, showing the single knee injection was generally well tolerated.
• Exploratory measures indicated sustained improvement in pain, stiffness, function through two years among patients who stayed in follow-up.
• Glucocorticoid pre-treatment appeared to improve tolerability and outcomes, shaping the ongoing Phase 2 ASCEND trial design.
• Phase 2 ASCEND topline results remain on track for a first readout at year-end 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.